Clinical Trial Update: IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 study (IMPACTS) evaluating varespladib, a phospholipase A2 inhibitor, for acute chest syndrome in sickle cell disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chest Syndrome
• Sickle Cell Disease
• Vaso-occlusive Crisis

Drugs mentioned

• Varespladib (varespladib)

Snippet

Sponsor: Anthera Pharmaceuticals | Conditions: Sickle Cell Disease, Vaso-occlusive Crisis | Phase 2 | Status: COMPLETED